Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial
Publication year
2019Source
Diabetes, Obesity & Metabolism, 21, 3, (2019), pp. 499-508ISSN
Publication type
Article / Letter to editor
Display more detailsDisplay less details
Organization
Internal Medicine
Journal title
Diabetes, Obesity & Metabolism
Volume
vol. 21
Issue
iss. 3
Page start
p. 499
Page end
p. 508
Subject
Radboudumc 6: Metabolic Disorders RIMLS: Radboud Institute for Molecular Life Sciences; Internal Medicine - Radboud University Medical Center; Radboud University Medical CenterThis item appears in the following Collection(s)
- Academic publications [245050]
- Electronic publications [132309]
- Faculty of Medical Sciences [93209]
- Open Access publications [105922]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.